171 related articles for article (PubMed ID: 11121912)
1. Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis.
García-Altés A; Jovell AJ; Serra-Prat M; Aymerich M
Aliment Pharmacol Ther; 2000 Dec; 14(12):1631-8. PubMed ID: 11121912
[TBL] [Abstract][Full Text] [Related]
2. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of the eradication of Helicobacter pylori as treatment for duodenal ulcer].
Fernández Muñoz J; López de Andrés A; Zapater Hernández P; Abad Santos F
An Med Interna; 1998 Oct; 15(10):515-22. PubMed ID: 9844225
[TBL] [Abstract][Full Text] [Related]
4. Is Helicobacter pylori eradication a cost-effective treatment of duodenal ulcer disease?
Carrere MO; Lamouliatte H; Ruszniewski P
Pharmacoeconomics; 1997 Mar; 11(3):216-24. PubMed ID: 10165311
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Badia X; Segú JL; Ollé A; Brosa M; Monés J; García Ponte L
Pharmacoeconomics; 1997 Apr; 11(4):367-76. PubMed ID: 10166411
[TBL] [Abstract][Full Text] [Related]
6. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
Craig AM; Davey P; Malek M; Murray F
Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers--a cost-effectiveness analysis.
Gené E; Calvet X; Azagra R
Aliment Pharmacol Ther; 2000 Apr; 14(4):433-42. PubMed ID: 10759623
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
9. A cost analysis of alternative treatments for duodenal ulcer.
Imperiale TF; Speroff T; Cebul RD; McCullough AJ
Ann Intern Med; 1995 Nov; 123(9):665-72. PubMed ID: 7574221
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
Wong BC; Lam SK; Lai KC; Hu WH; Ching CK; Ho J; Yuen ST; Chan CK; Lau GK; Lai CL
Aliment Pharmacol Ther; 1999 Mar; 13(3):303-9. PubMed ID: 10102962
[TBL] [Abstract][Full Text] [Related]
11. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease.
Cutler AF; Vakil N
Am J Manag Care; 1997 Oct; 3(10):1528-34. PubMed ID: 10178459
[TBL] [Abstract][Full Text] [Related]
12. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
[TBL] [Abstract][Full Text] [Related]
13. The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
Rosengren H; Polson RJ
Br J Gen Pract; 1996 Mar; 46(404):177-9. PubMed ID: 8731626
[TBL] [Abstract][Full Text] [Related]
14. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Duggan AE; Tolley K; Hawkey CJ; Logan RF
BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Rune SJ
Scand J Gastroenterol Suppl; 1994; 205():45-7. PubMed ID: 7863241
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Lehmann DF; Medicis JJ; Franklin PD
J Clin Pharmacol; 2003 Dec; 43(12):1316-23. PubMed ID: 14615467
[TBL] [Abstract][Full Text] [Related]
17. Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Chen SY; Wang JY; Chen J; Zhang XD; Zhang SS
J Gastroenterol Hepatol; 1999 Oct; 14(10):977-83. PubMed ID: 10530493
[TBL] [Abstract][Full Text] [Related]
18. [Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence].
Gisbert JP; Boixeda D; Aller R; de la Serna C; Sanz E; Martín de Argila C; Abraira V; García Plaza A
Med Clin (Barc); 1999 Feb; 112(5):161-5. PubMed ID: 10091208
[TBL] [Abstract][Full Text] [Related]
19. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects.
Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS
Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy.
Habu Y; Inokuchi H; Kiyota K; Hayashi K; Watanabe Y; Kawai K; Stålhammar NO
J Gastroenterol Hepatol; 1998 Mar; 13(3):280-7. PubMed ID: 9570241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
